Results 151 to 160 of about 154,929 (213)

Triple‐Negative Breast Cancer Cells Utilize IL8 and CXCL1 to Suppress NK Cells’ Function and Facilitate Cancer Metastasis

open access: yesAdvanced Science, EarlyView.
Triple‐negative breast cancer (TNBC) cells evade natural killer (NK) cell immunity by secreting IL8 and CXCL1. These chemokines suppress NK cells’ function via CXCR1/2 and enhance cancer cells’ survival through PD‐L1 upregulation and BCL‐2 anti‐apoptotic signaling.
Mingheng Yuan   +6 more
wiley   +1 more source

PANX2 Suppresses Lung Adenocarcinoma Progression by Inducing Disulfidptosis and Enhancing Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen   +7 more
wiley   +1 more source

BCMA‐Engineered Dendritic Cell‐Derived Exosomes as Bi‐Functional Therapeutics Orchestrating Cytokine Sequestration and Immune Activation for Multiple Myeloma

open access: yesAdvanced Science, EarlyView.
A dual‐function cell‐free therapeutic based on DC2.4 cell‐derived exosomes engineered to display BCMA. (Left) Soluble Ligand Sequestration (Decoy Function): DB Exo act as molecular decoys that predominantly sequester soluble APRIL with partial BAFF attenuation, effectively disrupting the NF‐κB survival signaling axis and suppressing myeloma cell ...
Yuqing Zeng   +5 more
wiley   +1 more source

Tumor‐Infiltrating mregDCs Restrain Anti‐Tumor Immunity in Early Relapse HCC

open access: yesAdvanced Science, EarlyView.
Tumor‐infiltrating mregDCs are regulated by the TNFR2‐non‐canonical NF‐κB axis, which is mediated by TNF‐α secreted by CD161+CD8+ T cells. These mregDCs recruit CD161+CD8+ T cells via the CCL20‐CCR6 axis, forming a positive feedback loop that enhances immunosuppression, promotes early recurrence of HCC, and further confirms TNFR2 as a key therapeutic ...
Zefan Zhang   +13 more
wiley   +1 more source

Tumor necrosis factor-α inhibitors and their effects on cardiovascular risk factorsin patients with rheumatoid arthritis

open access: yesНаучно-практическая ревматология, 2010
O G Lineva   +7 more
doaj   +1 more source

Targeting PLD3 Reverses the Immunosuppressive Niche by Reprogramming Tumor‐Associated Macrophages and Potentiates Antitumor Immunity

open access: yesAdvanced Science, EarlyView.
PLD3 activates the lysosomal‐AKT‐NF‐κB axis to drive cellular senescence in macrophages, establishing an immunosuppressive TME by limiting the infiltration of cytotoxic T, NK, and NKT cells, which confers resistance to anti‐PD‐1 therapy. Abrine inhibits PLD3 expression, restoring antitumor immunity and synergizing with anti‐PD‐1 treatment.
Xingtu Qin   +11 more
wiley   +1 more source

Bandgap‐Engineered PtxTey:Ag2Te Composite Quantum Dots Enable Programmable NIR‐II Imaging and Photothermal‐Immune Synergistic Therapy

open access: yesAdvanced Science, EarlyView.
A bandgap‐engineered PtxTey:Ag2Te quantum dot platform enables tunable NIR‐IIb emission for deep‐tissue imaging and mild photothermal therapy. Conjugation with αPD‐L1 confers dual tumor targeting and real‐time monitoring of PD‐L1 dynamics. Mild photothermal modulation induces immune reprogramming, enhancing checkpoint blockade efficacy and achieving ...
Jing Liu   +9 more
wiley   +1 more source

SSR4 sustains Tertiary Lymphoid Structures by Regulation Quality Control of N‐linked Glycosylation During B‐cell Differentiation Into Plasmacyte in Colorectal Cancer

open access: yesAdvanced Science, EarlyView.
SSR4, a TRAP component induced in B cells, governs BAFFR N‐glycosylation via DDOST to sustain NF‐κB signaling, B‐cell differentiation, and TLS maturation. Its loss impairs anti‐tumor immunity, while overexpression improves antibody glycosylation and ADCC, revealing a critical regulator for cancer immunotherapy.
Wei Zhao   +15 more
wiley   +1 more source

Home - About - Disclaimer - Privacy